The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Avidity Biosciences Inc (NASDAQ: RNA) closed at $32.49 down -3.76% from its previous closing price of $33.76. In other words, the price has decreased by -$3.76 from its previous closing price. On the day, 1.52 million shares were traded. RNA stock price reached its highest trading level at $34.78 during the session, while it also had its lowest trading level at $32.07.
Ratios:
For a deeper understanding of Avidity Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.76 and its Current Ratio is at 17.76. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on November 26, 2024, initiated with a Outperform rating and assigned the stock a target price of $67.
On September 24, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $59.
On August 28, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $63.Barclays initiated its Overweight rating on August 28, 2024, with a $63 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 11 ’24 when Flanagan W. Michael sold 24,000 shares for $35.77 per share. The transaction valued at 858,401 led to the insider holds 85,389 shares of the business.
W. MICHAEL FLANAGAN bought 24,000 shares of RNA for $866,400 on Dec 11 ’24. On Nov 18 ’24, another insider, McCarthy Teresa, who serves as the Chief Human Resources Officer of the company, sold 25,000 shares for $41.14 each. As a result, the insider received 1,028,520 and left with 94,018 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 3876349696 and an Enterprise Value of 2295367680. For the stock, the TTM Price-to-Sale (P/S) ratio is 368.63 while its Price-to-Book (P/B) ratio in mrq is 2.57. Its current Enterprise Value per Revenue stands at 226.882 whereas that against EBITDA is -7.128.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $6.79. The 50-Day Moving Average of the stock is -25.81%, while the 200-Day Moving Average is calculated to be -11.84%.
Shares Statistics:
For the past three months, RNA has traded an average of 1.29M shares per day and 1289330 over the past ten days. A total of 118.90M shares are outstanding, with a floating share count of 108.48M. Insiders hold about 9.07% of the company’s shares, while institutions hold 101.10% stake in the company. Shares short for RNA as of 1732838400 were 14935394 with a Short Ratio of 11.62, compared to 1730332800 on 14659552. Therefore, it implies a Short% of Shares Outstanding of 14935394 and a Short% of Float of 15.439998999999998.
